BioIndustry Ethics

by David L. Finegold, Cecile M Bensimon, Abdallah S. Daar, Margaret L. Eaton, Beatrice Godard

Overview

This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.

Product Details

ISBN-13:	9780123693709
Publisher:	Elsevier Science
Publication date:	06/01/2005
Edition description:	New Edition
Pages:	384
Product dimensions:	0.79(w) x 6.00(h) x 9.00(d)

Table of Contents

Chapter 1: INTRODUCTION

Chapter 2: MERCK: STAYING THE COURSE

Chapter 3: GENZYME: PUTTING PATIENTS FIRST

Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES

Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES

Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS

Chapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS

Chapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTS

Chapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP

Chapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE

Chapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE

Chapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD

Chapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEER

Chapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINE

Chapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES

INDEX

Editorial Reviews

"Biotechnology and pharmaceutical companies are often driven by profit goals, but the case studies in Bioindustry Ethics show that this is increasingly not at the expense of ethical integrity. ...lend[s] important insights to other executives and professionals who might be developing their own practices and policies."
- GENOMICS & PROTEOMICS (August 2005)

From the Publisher